Format

Send to

Choose Destination
Nat Biotechnol. 1998 Jun;16(6):556-61.

A nuclease-resistant protein kinase C alpha ribozyme blocks glioma cell growth.

Author information

1
Department of Immunology, Norwegian Radium Hospital, Montebello, Oslo, Norway. mosioud@embnet.uio.no

Abstract

We investigated the cleavage activity, stability, and efficacy of 2'-amino pyrimidine modified ribozymes on malignant glioma growth. A synthetic protein kinase C alpha (PKC alpha) ribozyme with complete pyrimidine nucleotide substitution retained a comparable cleavage activity compared with the unmodified ribozyme. The half-life of the modified ribozyme in serum was increased 14,000-fold compared with the unmodified version. The PKC alpha modified ribozyme inhibited glioma cell growth in vitro as a result of the inhibition of PKC alpha gene expression. A single injection of cationic liposome ribozyme complexes into glioma tumors inhibited tumor growth, demonstrating both the efficacy of the ribozyme and a major role of PKC alpha in tumor growth.

PMID:
9624687
DOI:
10.1038/nbt0698-556
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center